Cephagenix | Valuation, Funding Rounds & Stock Price | Caplight

Cephagenix

Private
Paris
Healthcare & Life Sciences
https://cephagenix.com/

Last Round
Seed
Jan 15, 2025

Total Funding Raised
$9.27M

Company Overview

Cephagenix is a drug discovery company that develops novel migraine treatments by identifying and developing selective inhibitors of the ATP-sensitive potassium channel subtype expressed in intracranial arteries.

Sector
Healthcare & Life Sciences

Verticals
Biotechnology, Drug Discovery

Business Model
B2B

Customer Profile
Services & Consulting

AI Layer
Non-AI

Keywords
migraine treatment, drug discovery, biopharmaceutical, pharma R&D, migraine drug, ion channel research, KATP channel inhibitors, clinical-stage biotech, biotech startup, migraine therapy, preclinical development, drug licensing, vascular medicine, therapeutic pipeline

Cephagenix Comparables

Compare Cephagenix with similar companies based on industry and business-model similarity.

Company Similarity Market Cap
Slate Medicines 78%
Vedana Therapeutics 71%
H. Lundbeck A/S 67%
Comparable company 50%

Cephagenix Funding Rounds

Historical fundraising activity

Round Date Amount Raised Valuation Investors Sources
Seed Jan 15, 2025

Cephagenix Investors

Notable investors and investment history

Investor Rounds
AbbVie Ventures Seed
AdBio partners Seed

Cephagenix Filings

SEC and related filings with document metadata.

Typed Date Amount Offered Amount Sold Filling Pages Download
Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation

Frequently Asked Questions

Common questions about Cephagenix's valuation, stock price, and market status.

Firmographic Details

Headquarters Paris
Year Founded 2020
Last Funding Jan 15, 2025